Clinical Pharmacokinetics

, Volume 36, Issue 2, pp 115–126 | Cite as

Clinical Pharmacokinetics of Meloxicam

A Cyclo-Oxygenase-2 Preferential Nonsteroidal Anti-Inflammatory Drug
Review Articles Drug Disposition

Abstract

Meloxicam [4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide] is a nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class which shows preferential inhibition of cyclooxygenase-2.

Meloxicam has a plasma half-life of approximately 20 hours, making it convenient for once-daily administration. Meloxicam is eliminated after biotransformation to 4 pharmacologically inactive metabolites, which are excreted in urine and faeces. Meloxicam and its metabolites bind extensively to plasma albumin. Substantial concentrations of meloxicam are attained in synovial fluid, the proposed site of action in chronic inflammatory arthropathies.

Neither moderate renal nor hepatic insufficiency significantly alter the pharmacokinetics of meloxicam. Dosage adjustment is not required in the elderly. Drug-drug interaction studies are available for some commonly co-prescribed medications. Concentration-dependent therapeutic and toxicological effects have yet to be extensively elucidated for this NSAID.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Engelhardt G, Homma D, Schlegel K, et al. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm Res 1995; 44 (10): 423–33.PubMedCrossRefGoogle Scholar
  2. 2.
    Luger P, Daneck K, Engel W, et al. Structure and physiochemical properties of meloxicam, a new NSATD. Eur J Pharm Sci 1996; 4 (3): 175–87.CrossRefGoogle Scholar
  3. 3.
    Albengres E, Urien S, Barre J, et al. Clinical pharmacology of oxicams: new insights into the mechanisms of their dose-dependent toxicity. Int J Tissue React 1993; 15 (3): 125–34.PubMedGoogle Scholar
  4. 4.
    Roszko P. Meloxicam: a COX-2 preferential NSATD. TBC’s Industry Symposium on COX-2 Inhibitors. Applications in Inflammation, Cancer, and Alzheimer’s Disease: 1998 Aug 6–7; San Diego. In press.Google Scholar
  5. 5.
    Noble S, Balfour JA. Meloxicam. Drugs 1996; 51 (3): 424–30; discussion 431–32.PubMedCrossRefGoogle Scholar
  6. 6.
    Türck D, Roth W, Busch U. A review of the clinical pharmacokinetics of meloxicam. Br J Rheumatol 1996; 35 Suppl. 1: 13–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Türck D, Busch U, Heinzel G, et al. Basic clinical pharmacokinetics of meloxicam, a new NSAID [abstract]. Scand J Rheumatol 1994; S98: A120.Google Scholar
  8. 8.
    Türck D, Busch U, Heinzel G, et al. Clinical pharmacokinetics of meloxicam. Arzneimittel Forschung 1997; 47 (3): 253–8.PubMedGoogle Scholar
  9. 9.
    Busch U, Heinzel G, Narjes H. Effect of food on pharmacokinetics of meloxicam, a new non steroidal anti-inflammatory drug (NSAID). Agents Actions 1991; 32 (1–2): 52–3.PubMedCrossRefGoogle Scholar
  10. 10.
    Narjes H, Türck D, Busch U, et al. Pharmacokinetics and tolerability of meloxicam after i.m. administration. Br J Clin Pharmacol 1996; 41 (2): 135–9.CrossRefGoogle Scholar
  11. 11.
    Schmid J, Busch U, Heinzel G, et al. Pharmacokinetics and metabolic pattern after intravenous infusion and oral administration to healthy subjects. Drug Metab Dispos 1995; 23 (11): 1206–13.PubMedGoogle Scholar
  12. 12.
    Degner F, Heinzl G, Busch U. Transsynovial kinetics of meloxicam [abstract]. Scand J Rheumatol 1994; S98: A121.Google Scholar
  13. 13.
    Jolliet P, Simon N, Bree F, et al. Blood-to-brain transfer of various oxicams: effects of plasma binding on their brain delivery. Pharm Res 1997; 14 (5): 650–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Chesne C, Guyomard C, Guillouzo A, et al. Metabolism of meloxicam in human liver involves cytochromes P4502C9 and 3A4. Xenobiotica 1998; 28 (1): 1–13.PubMedCrossRefGoogle Scholar
  15. 15.
    Auvinet B, Ziller R, Appelboom T, et al. Comparison of the onset and intensity of action of intramuscular meloxicam and oral meloxicam in patients with acute sciatica. Clin Ther 1995; 17 (6): 1078–98.PubMedCrossRefGoogle Scholar
  16. 16.
    Davies NM, Anderson KE. Clinical pharmacokinetics of diclofenac: therapeutic insights and pitfalls. Clin Pharmacokinet 1997; 33 (3): 184–213.PubMedCrossRefGoogle Scholar
  17. 17.
    Engelhardt G, Trummlitz G. Biological activity of the main metabolites of meloxicam. Drugs Exp Clin Res 1990; 16 (2): 53–6.PubMedGoogle Scholar
  18. 18.
    Sander O, Hübner G, Türck D, et al. Meloxicam pharmacokinetics in elderly compared to younger male and female patients with rheumatoid arthritis. Rheumatol Eur 1995; 24 (S3): 221.Google Scholar
  19. 19.
    Boulton-Jones JM, Geddes CG, Heinzel G, et al. Meloxicam pharmacokinetics in renal impairment. Br J Clin Pharmacol 1997; 43 (1): 35–40.PubMedCrossRefGoogle Scholar
  20. 20.
    Bevis PJ, Bird HA, Lapham G. An open study to assess the safety and tolerability of meloxicam 15 mg in subjects with rheumatic disease and mild renal impairment. Br J Rheumatol 1996; 35 Suppl. 1: 56–60.PubMedCrossRefGoogle Scholar
  21. 21.
    Türck D, Schwarz A, Hoffler D, et al. Pharmacokinetics of meloxicam in patients with end-stage renal failure on haemodialysis: a comparison with healthy volunteers. Eur J Clin Pharmacol 1996; 51 (3–4): 309–13.PubMedCrossRefGoogle Scholar
  22. 22.
    Busch U, Heinzel G, Narjes H, et al. Pharmacokinetics of meloxicam in patients with liver insufficiency associated with liver cirrhosis. Rheumatol Eur 1995; 24 (S3): 177.Google Scholar
  23. 23.
    Türck D, Su CA, Heinzel G, et al. Lack of interaction between meloxicam and warfarin in healthy volunteers. Eur J Clin Pharmacol 1997; 51 (5): 421–5.PubMedCrossRefGoogle Scholar
  24. 24.
    Degner FL, Heinzel G, Narjes H, et al. The effect of meloxicam on the pharmacokinetics of beta-acetyl-digoxin. Br J Clin Pharmacol 1995; 40 (5): 486–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Muller FO, Schall R, de Vaal AC, et al. Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers. Eur J Clin Pharmacol 1995; 48 (3–4): 247–51.PubMedCrossRefGoogle Scholar
  26. 26.
    Müller FO, Middle MV, Schall R, et al. An evaluation of the interaction of meloxicam with frusemide in patients with compensated chronic cardiac failure. Br J Clin Pharmacol 1997; 44 (4): 393–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Hubner G, Sander O, Degner FL, et al. Lack of pharmacokinetic interaction of meloxicam with methotrexate in patients with rheumatoid arthritis. J Rheumatol 1997; 24 (5): 845–51.PubMedGoogle Scholar
  28. 28.
    Busch U, Heinzel G, Narjes H, et al. Interaction of meloxicam with Cimetidine, Maalox, or aspirin. J Clin Pharmacol 1996; 36 (1): 79–84.PubMedGoogle Scholar
  29. 29.
    Busch U, Heinzel G, Narjes H. The effect of cholestyramine on the pharmacokinetics of meloxicam, a new non-steroidal antiinflammatory drug (NSAID), in man. Eur J Clin Pharmacol 1995; 48 (3–4): 269–72.PubMedCrossRefGoogle Scholar
  30. 30.
    Pairet M, van Ryn J. Experimental models used to investigate the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2 by non-steroidal anti-inflammatory drugs. Inflamm Res 1998; 47 Suppl. 2: S93–101.PubMedCrossRefGoogle Scholar
  31. 31.
    Pairet M, van Ryn J, Schierok H, et al. Differential inhibition of cyclooxygenases-1 and -2 by meloxicam and its 4′-isomer. Inflamm Res 1998; 47 (6): 270–6.PubMedCrossRefGoogle Scholar
  32. 32.
    Forsyth SF, Guilford WG, Haslett SJ, et al. Endoscopy of the gastroduodenal mucosa after carprofen, meloxicam and ketoprofen administration in dogs. J Small Anim Pract 1998; 39 (9): 421–4.PubMedCrossRefGoogle Scholar
  33. 33.
    Lipscomb GR, Wallis N, Armstrong G, et al. Gastrointestinal tolerability of meloxicam and piroxicam: a double-blind placebo-controlled study. Br J Clin Pharmacol 1998; 46 (2): 133–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Hawkey C, Kahan A, Steinbruck K, International Meloxicam Large-Scale International Study Safety Assessment (MELISSA) Study Group, et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. Br J Rheumatol 1998; 37 (9): 937–45.PubMedCrossRefGoogle Scholar
  35. 35.
    Dequeker J, Hawkey C, Kahan A, et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-Inhibiting Therapies (SELECT) trial in osteoarthritis. Br J Rheumatol 1998; 37 (9): 946–51.PubMedCrossRefGoogle Scholar
  36. 36.
    Bayerl C, Pagung R, Jung EG. Meloxicam in acute UV dermatitis: a pilot study. Photodermatol Photoimmunol Photomed 1998; 14 (5–6): 167–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Lopez-Garcia JA, Laird JM. Central antinociceptive effects of meloxicam on rat spinal cord in vitro. Neuroreport 1998; 9 (4): 647–51.PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1999

Authors and Affiliations

  1. 1.Department of Pharmaceutics, School of Pharmacy, College of Health SciencesUniversity of SydneySydneyAustralia
  2. 2.Respiratory Research Group Faculty of MedicineUniversity of CalgaryCalgaryCanada

Personalised recommendations